Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966761 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2GNAI3GNAO1GNAI1GAA | |
| Hydrochloric Acid SCHEMBL21066954 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2GNAI3GNAO1GNAI1ALOX15 | |
| SCHEMBL5878419 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2GAAALDH1A1KDM4ELMNA | |
| SCHEMBL1077689 | 0.83 | GNAI3 (0.49) | SMN1; SMN2GNAI3GNAO1GNAI1ALOX15 | |
| SCHEMBL27362424 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2GAAALDH1A1KDM4ELMNA | |
| SCHEMBL23936834 | 0.82 | GNAI3 (0.51) | SMN1; SMN2GNAI3GNAO1GNAI1ALOX15 | |
| SCHEMBL17672623 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2GAAALDH1A1KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL27483975 | 0.82 | GNAI3 (0.51) | SMN1; SMN2GNAI3GNAO1GNAI1ALOX15 | |
| SCHEMBL5803382 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2GAAALDH1A1KDM4ELMNA | |
| SCHEMBL1438742 | 0.82 | SMN1; SMN2 (0.71) | SMN1; SMN2GNAI3GNAO1GNAI1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2025-02-20 | — | — | US | disclosed |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-12-26 | — | — | US | disclosed |
| CN-118414171-A | Oligosaccharide complexes and uses | 生物技术公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118401538-A | Oligosaccharide compounds and complexes | 生物技术公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-4401838-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401789-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401788-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| CN-118369122-A | Oligosaccharide complex and use thereof | 生物技术公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-4285932-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2023-12-06 | — | — | EP | disclosed |
| EP-4285933-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2023-12-06 | — | — | EP | disclosed |
| EP-4286003-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023067125-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067125-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067121-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067123-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067123-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2023-04-27 | — | — | WO | disclosed |
| EP-3475277-B1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-10-20 | — | — | EP | disclosed |
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC | 2012-04-05 | — | — | US | disclosed |
| WO-2010141539-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | FUT6, NSUN3, OSTC | SMN1; SMN2 1295/4885GNAI3 1253/4885GNAO1 545/4885 |
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | SMN1; SMN2 3874/4885GNAI3 2135/4885GNAO1 1741/4885 |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CD4, FUT6, UGCG | SMN1; SMN2 3923/4885GNAI3 1359/4885GNAO1 757/4885 |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | OSTC, SNRPA, RNASE1 | SMN1; SMN2 426/4885GNAI3 2734/4885GNAO1 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.